Radioiodine (RAI) therapy has been one of the primary systemic therapy options for
metastatic thyroid cancer of follicular cell origin for more than 50 years. While often very …

For more than 50 years, radioactive iodine has been effectively used to treat metastatic
thyroid cancer (1). Dramatic therapeutic responses are often seen when the metastatic foci …

The cumulative evidence over the past decades has shown that the incidence of
differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of …

Radioiodine (RAI)-refractory thyroid cancer is an uncommon entity, occurring with an
estimated incidence of 4-5 cases/year/million people. RAI refractoriness is more frequent in …

Background: Sorafenib and lenvatinib are multikinase inhibitors (MKIs) approved for patients
with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). There is no …

Multikinase inhibitors for the treatment of radioiodine refr... : Current Opinion in Oncology
Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have …

Background MKIs effectively prolong progression-free survival in patients with RAI-R DTC,
but are associated with notable toxicity. There is currently no consensus on when patients …

Background The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with
radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear …

The Society of Nuclear Medicine and Molecular Imaging appreciates the opportunity to
comment on the article by Molenaar et al 1 that explores the risks of developing secondary …

Patients with radioactive iodine (RAI) refractory locally advanced or metastatic differentiated
thyroid cancer have a poor prognosis. This article reviews the definition of RAI-refractory …